Different anti-SARS-CoV-2 vaccine response under B- and T-cell targeted therapies versus anti-cytokine therapies in patients with inflammatory arthritides
Renaud Felten(Centre National de la Recherche Scientifique), Jean-Hugues Salmon(Centre Hospitalier Universitaire de Reims), Rose‐Marie Javier(Laboratoire National de Référence), M. Geoffroy(Centre Hospitalier Universitaire de Reims), Luc Pijnenburg(Hôpitaux Universitaires de Strasbourg), A. Fan(Centre Hospitalier Universitaire de Clermont-Ferrand), Christelle Sordet, Martin Soubrier(Centre Hospitalier Universitaire de Clermont-Ferrand), Messer Laurent(Hopitaux Civils de Colmar), Pierre‐Marie Duret(Hopitaux Civils de Colmar), Marion Couderc(Centre Hospitalier Universitaire de Clermont-Ferrand), Samira Ahmed-Yahia(Hôpitaux Universitaires de Strasbourg), Emmanuel Chatelus(Laboratoire National de Référence), Jean Sibilia(Immunologie, Immunopathologie et Chimie Thérapeutique), Marie Desmurs, Jacques‐Eric Gottenberg(Hôpitaux Universitaires de Strasbourg), L. Bolko(Centre Hospitalier Universitaire de Reims), M. Ardizzone(Centre Hospitalier de Mulhouse), Alain Meyer(Hôpitaux Universitaires de Strasbourg)
Cited by 1
Related Papers
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k
A multicenter, randomized, double‐blind, placebo‐controlled trial of adjuvant methotrexate treatment for giant cell arteritis
|Arthritis & Rheumatism|2002|574
<i>MUC5B</i> Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease
|New England Journal of Medicine|2018|501
Incidence and Prevalence of Systemic Sclerosis: A Systematic Literature Review
|Seminars in Arthritis and Rheumatism|2007|456